Extended follow up of high-dose melphalan and autologous stem cell transplantation after vincristine, doxorubicin, dexamethasone induction in amyloid light chain amyloidosis of the prospective phase II HOVON-41 study by the Dutch-Belgian Co-operative Trial Group for Hematology Oncology

Bouke P. C. Hazenberg, Alexandra Croockewit, Bronno van der Holt, Sonja Zweegman, Gerard M. J. Bos, Michel Delforge, Reinier A. P. Raymakers, Pieter Sonneveld, Edo Vellenga, Pierre W. Wijermans, Peter A. von dem Borne, Marinus H. van Oers, Okke de Weerdt, Fokje M. Spoelstra, Henk M. Lokhorst

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)677-682
JournalHaematologica-the Hematology Journal
Volume100
Issue number5
DOIs
Publication statusPublished - May 2015

Cite this

Hazenberg, B. P. C., Croockewit, A., van der Holt, B., Zweegman, S., Bos, G. M. J., Delforge, M., Raymakers, R. A. P., Sonneveld, P., Vellenga, E., Wijermans, P. W., von dem Borne, P. A., van Oers, M. H., de Weerdt, O., Spoelstra, F. M., & Lokhorst, H. M. (2015). Extended follow up of high-dose melphalan and autologous stem cell transplantation after vincristine, doxorubicin, dexamethasone induction in amyloid light chain amyloidosis of the prospective phase II HOVON-41 study by the Dutch-Belgian Co-operative Trial Group for Hematology Oncology. Haematologica-the Hematology Journal, 100(5), 677-682. https://doi.org/10.3324/haematol.2014.119198